Involvement of free radicals and oxidative stress in NAFLD/NASH
暂无分享,去创建一个
[1] E. Niki. Biomarkers of lipid peroxidation in clinical material. , 2014, Biochimica et biophysica acta.
[2] E. Niki. Role of vitamin E as a lipid-soluble peroxyl radical scavenger: in vitro and in vivo evidence. , 2014, Free radical biology & medicine.
[3] H. Guillou,et al. The liver X receptor: a master regulator of the gut-liver axis and a target for non alcoholic fatty liver disease. , 2013, Biochemical pharmacology.
[4] M. Speechley,et al. Phase II clinical trial of phlebotomy for non‐alcoholic fatty liver disease , 2013, Alimentary pharmacology & therapeutics.
[5] C. Kiyose,et al. Effects of tocotrienol on tumor necrosis factor-α/d-galactosamine-induced steatohepatitis in rats , 2013, Journal of clinical biochemistry and nutrition.
[6] N. Nieto,et al. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. , 2013, Journal of hepatology.
[7] T. Ikeda,et al. Dysregulated expression of fatty acid oxidation enzymes and iron‐regulatory genes in livers of Nrf2‐null mice , 2012, Journal of gastroenterology and hepatology.
[8] A. Sanyal,et al. Vitamin E and nonalcoholic fatty liver disease , 2012, Current opinion in clinical nutrition and metabolic care.
[9] C. Pignata,et al. Therapeutic options in pediatric non alcoholic fatty liver disease: current status and future directions , 2012, Italian Journal of Pediatrics.
[10] S. Hazen,et al. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: New evidence on the potential therapeutic mechanism , 2012, Hepatology.
[11] K. Safranow,et al. Lipidic last breath of life in patients with alcoholic liver disease. , 2012, Prostaglandins & other lipid mediators.
[12] A. Sanyal,et al. Metabolomic Profiling to Identify Predictors of Response to Vitamin E for Non-Alcoholic Steatohepatitis (NASH) , 2012, PloS one.
[13] J. Manautou,et al. Nrf2: A Potential Target for New Therapeutics in Liver Disease , 2012, Clinical pharmacology and therapeutics.
[14] S. Fargion,et al. Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease. , 2012, World journal of gastroenterology.
[15] A. Wierzbicki,et al. Nonalcoholic fatty liver disease and lipids , 2012, Current opinion in lipidology.
[16] K. Cusi,et al. Corrigendum:The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.
[17] K. Cusi,et al. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.
[18] T. Miyazaki,et al. Increased serum liver X receptor ligand oxysterols in patients with non-alcoholic fatty liver disease , 2012, Journal of Gastroenterology.
[19] E. Niki,et al. Fatty liver induced by free radicals and lipid peroxidation , 2012, Free radical research.
[20] C. Lawton,et al. Vitamin E and the Risk of Prostate Cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) , 2012 .
[21] C. Palmeira,et al. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. , 2012, Free Radical Biology & Medicine.
[22] A. Feldstein,et al. Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo‐controlled trial , 2011, Hepatology.
[23] Jianqiang Guo,et al. Upregulation of Nrf2 expression in non-alcoholic fatty liver and steatohepatitis. , 2011, Hepato-gastroenterology.
[24] J. Crowley,et al. Vitamin E and the Risk of Prostate Cancer The Selenium and Vitamin E Cancer Prevention Trial ( SELECT ) , 2011 .
[25] L. N. Valenti,et al. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. , 2011, Journal of hepatology.
[26] B. Fromenty,et al. Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role. , 2011, Clinics and research in hepatology and gastroenterology.
[27] L. Iuliano. Pathways of cholesterol oxidation via non-enzymatic mechanisms. , 2011, Chemistry and physics of lipids.
[28] H. Yin,et al. Free radical lipid peroxidation: mechanisms and analysis. , 2011, Chemical reviews.
[29] A. Bast,et al. The role of oxidative stress in non-alcoholic steatohepatitis. , 2011, Clinica chimica acta; international journal of clinical chemistry.
[30] R. Green,et al. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. , 2011, Annals of hepatology.
[31] Guolin Li,et al. Plasma reactive carbonyl species levels and risk of non‐alcoholic fatty liver disease , 2011, Journal of gastroenterology and hepatology.
[32] V. de Lédinghen,et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. , 2011, Journal of hepatology.
[33] P. Rosenthal,et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. , 2011, JAMA.
[34] D. Häussinger,et al. Plasma levels of vitamin E and carotenoids are decreased in patients with nonalcoholic steatohepatitis (NASH) , 2011, European journal of medical research.
[35] M. Davies. Myeloperoxidase-derived oxidation: mechanisms of biological damage and its prevention , 2010, Journal of clinical biochemistry and nutrition.
[36] P. Kochanek,et al. Mass‐spectrometry based oxidative lipidomics and lipid imaging: applications in traumatic brain injury , 2010, Journal of neurochemistry.
[37] R. Bruno,et al. Dietary α- and γ-tocopherol supplementation attenuates lipopolysaccharide-induced oxidative stress and inflammatory-related responses in an obese mouse model of nonalcoholic steatohepatitis. , 2010, The Journal of nutritional biochemistry.
[38] April D. Lake,et al. Diversity in Antioxidant Response Enzymes in Progressive Stages of Human Nonalcoholic Fatty Liver Disease , 2010, Drug Metabolism and Disposition.
[39] K. Itoh,et al. Discovery of the negative regulator of Nrf2, Keap1: a historical overview. , 2010, Antioxidants & redox signaling.
[40] S. Hazen,et al. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[S] , 2010, Journal of Lipid Research.
[41] E. Niki. Assessment of antioxidant capacity in vitro and in vivo. , 2010, Free radical biology & medicine.
[42] T. Berg,et al. High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double‐blind, randomized, placebo‐controlled trial , 2010, Hepatology.
[43] F. Galvano,et al. l-Carnitine Supplementation to Diet: A New Tool in Treatment of Nonalcoholic Steatohepatitis—A Randomized and Controlled Clinical Trial , 2010, The American Journal of Gastroenterology.
[44] B. Neuschwander‐Tetri,et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.
[45] W. Schunck,et al. Cytochrome P450-dependent metabolism of ω-6 and ω-3 long-chain polyunsaturated fatty acids , 2010 .
[46] M. Khoshbaten,et al. N-Acetylcysteine Improves Liver Function in Patients with Non-Alcoholic Fatty Liver Disease , 2010, Hepatitis monthly.
[47] J. Hayes,et al. Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. , 2010, Free radical biology & medicine.
[48] Hirokazu Takahashi,et al. The pathological role of visceral fat accumulation in steatosis, inflammation, and progression of nonalcoholic fatty liver disease , 2010, Journal of Gastroenterology.
[49] Michelle M Wiest,et al. The plasma lipidomic signature of nonalcoholic steatohepatitis , 2009, Hepatology.
[50] S. Sanderson,et al. Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo‐controlled trial , 2009, Hepatology.
[51] E. Niki. Lipid peroxidation: physiological levels and dual biological effects. , 2009, Free radical biology & medicine.
[52] H. Szajewska,et al. Pharmacological Interventions for Nonalcoholic Fatty Liver Disease in Adults and in Children: A Systematic Review , 2009, Journal of pediatric gastroenterology and nutrition.
[53] F. Nicoletti,et al. Molecular mechanisms involved in NAFLD progression , 2009, Journal of Molecular Medicine.
[54] M. Davies,et al. What are the plasma targets of the oxidant hypochlorous acid? A kinetic modeling approach. , 2009, Chemical research in toxicology.
[55] R. Bataller,et al. Increased susceptibility to exacerbated liver injury in hypercholesterolemic ApoE-deficient mice: potential involvement of oxysterols. , 2009, American journal of physiology. Gastrointestinal and liver physiology.
[56] T. Okanoue,et al. Role of hepatic iron in non‐alcoholic steatohepatitis , 2009, Hepatology research : the official journal of the Japan Society of Hepatology.
[57] Y. Takei,et al. Iron Overload Is Associated with Hepatic Oxidative Damage to DNA in Nonalcoholic Steatohepatitis , 2009, Cancer Epidemiology Biomarkers & Prevention.
[58] Jun Yu,et al. Antioxidants vitamin E and 1-aminobenzotriazole prevent experimental non-alcoholic steatohepatitis in mice , 2009, Scandinavian journal of gastroenterology.
[59] I. Ichi,et al. Effect of α-tocopherol on carbon tetrachloride intoxication in the rat liver , 2009, Archives of Toxicology.
[60] N. Anderson,et al. Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis , 2008, Pharmacological Reviews.
[61] R. Murphy,et al. Cholesterol, Reactive Oxygen Species, and the Formation of Biologically Active Mediators* , 2008, Journal of Biological Chemistry.
[62] A. Cederbaum,et al. CYP2E1 and oxidative liver injury by alcohol. , 2008, Free radical biology & medicine.
[63] C. Wai,et al. A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH) , 2008, Hepatology international.
[64] P. Ravasco,et al. Blood oxidative stress markers in non-alcoholic steatohepatitis and how it correlates with diet , 2008, Scandinavian journal of gastroenterology.
[65] K. Jishage,et al. Acceleration of lipid peroxidation in alpha-tocopherol transfer protein-knockout mice following the consumption of drinking water containing a radical initiator. , 2008, Journal of oleo science.
[66] F. Guengerich. Cytochrome p450 and chemical toxicology. , 2008, Chemical research in toxicology.
[67] R. Malekzadeh,et al. Liver Histology Changes in Nonalcoholic Steatohepatitis after One Year of Treatment with Probucol , 2008, Digestive Diseases and Sciences.
[68] M. Honda,et al. Lipid‐induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet , 2007, Hepatology.
[69] E. Niki. Tocopherylquinone and tocopherylhydroquinone , 2007, Redox report : communications in free radical research.
[70] L. N. Valenti,et al. Iron Depletion by Phlebotomy Improves Insulin Resistance in Patients With Nonalcoholic Fatty Liver Disease and Hyperferritinemia: Evidence from a Case-Control Study , 2007, The American Journal of Gastroenterology.
[71] T. Yoshikawa,et al. Lipid peroxidation and lysosomal enzymes in D-galactosamine hepatitis and its protection by vitamin E , 2007, Gastroenterologia Japonica.
[72] A. Federico,et al. The Effect of a Silybin-Vitamin E-Phospholipid Complex on Nonalcoholic Fatty Liver Disease: A Pilot Study , 2007, Digestive Diseases and Sciences.
[73] R. Rodrigo,et al. Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. , 2006, Trends in molecular medicine.
[74] J. Dufour,et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[75] T. Okanoue,et al. Effect of iron reduction by phlebotomy in Japanese patients with nonalcoholic steatohepatitis: A pilot study. , 2006, Hepatology research : the official journal of the Japan Society of Hepatology.
[76] Y. Jeon,et al. A water extract of Artemisia capillaris prevents 2,2'-azobis(2-amidinopropane) dihydrochloride-induced liver damage in rats. , 2006, Journal of medicinal food.
[77] F. Nicoletti,et al. Chitotriosidase gene expression in Kupffer cells from patients with non-alcoholic fatty liver disease , 2006, Gut.
[78] I. Pikuleva. CHOLESTEROL-METABOLIZING CYTOCHROMES P450 , 2006, Drug Metabolism and Disposition.
[79] A. Cederbaum,et al. Nrf2 is increased by CYP2E1 in rodent liver and HepG2 cells and protects against oxidative stress caused by CYP2E1 , 2006, Hepatology.
[80] R. Rodrigo,et al. Relationship between in vivo chlorzoxazone hydroxylation, hepatic cytochrome P450 2E1 content and liver injury in obese non-alcoholic fatty liver disease patients. , 2006, Hepatology research : the official journal of the Japan Society of Hepatology.
[81] O. Erel,et al. Measurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis , 2005, BMC gastroenterology.
[82] K. Jishage,et al. Lipid peroxidation induced by carbon tetrachloride and its inhibition by antioxidant as evaluated by an oxidative stress marker, HODE. , 2005, Toxicology and applied pharmacology.
[83] M. Vidali,et al. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis , 2005, Gut.
[84] M. Malaguarnera,et al. Heme oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients. , 2005, Journal of hepatology.
[85] B. Zilberstein,et al. Lipid Peroxidation in Bariatric Candidates with Nonalcoholic Fatty Liver Disease (NAFLD) – Preliminary Findings , 2005, Obesity surgery.
[86] E. Çakır,et al. Systemic Markers of Lipid Peroxidation and Antioxidants in Patients with Nonalcoholic Fatty Liver Disease , 2005, The American Journal of Gastroenterology.
[87] P. Kar,et al. Non-alcoholic steatohepatitis. , 2005, The Journal of the Association of Physicians of India.
[88] S. Gawrieh,et al. Oxidative Stress in Nonalcoholic Fatty Liver Disease: Pathogenesis and Antioxidant Therapies , 2004, Journal of Investigative Medicine.
[89] N. Chalasani,et al. Systemic Levels of Lipid Peroxidation and Its Metabolic and Dietary Correlates in Patients with Nonalcoholic Steatohepatitis , 2004, American Journal of Gastroenterology.
[90] J. Yodoi,et al. Control of oxidative stress and reduction in biochemical markers by Vitamin E treatment in patients with nonalcoholic steatohepatitis: a pilot study. , 2004, Hepatology research : the official journal of the Japan Society of Hepatology.
[91] L. Burgart,et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial , 2004, Hepatology.
[92] R. Rodrigo,et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. , 2004, Clinical science.
[93] A. Cederbaum,et al. Oxidative stress, toxicology, and pharmacology of CYP2E1. , 2004, Annual review of pharmacology and toxicology.
[94] M. Koruk,et al. Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis. , 2004, Annals of clinical and laboratory science.
[95] P. Hayashi,et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis , 2003, American Journal of Gastroenterology.
[96] C. McClain,et al. Cytokines and NASH: A pilot study of the effects of lifestyle modification and vitamin E , 2003, Hepatology.
[97] R. Malekzadeh,et al. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. , 2003, Journal of hepatology.
[98] J. Yodoi,et al. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. , 2003, Journal of hepatology.
[99] Defeng Wu,et al. Alcohol, Oxidative Stress, and Free Radical Damage , 2003, Alcohol research & health : the journal of the National Institute on Alcohol Abuse and Alcoholism.
[100] S. Seki,et al. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. , 2002, Journal of hepatology.
[101] N. Noguchi,et al. The Specificity of Lipoxygenase-Catalyzed Lipid Peroxidation and the Effects of Radical- Scavenging Antioxidants , 2002, Biological chemistry.
[102] V. Preedy,et al. Effect of Chronic Ethanol Feeding on Oxysterols in Rat Liver , 2002, Free radical research.
[103] A. Di Carlo,et al. Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. , 2001, Journal of hepatology.
[104] A. Terano,et al. Plasma transforming growth factor‐β1 level and efficacy of α‐tocopherol in patients with non‐alcoholic steatohepatitis: a pilot study , 2001, Alimentary pharmacology & therapeutics.
[105] K. Lindor,et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study , 2001, American Journal of Gastroenterology.
[106] S. Basu,et al. Vitamin E reduces lipid peroxidation in experimental hepatotoxicity in rats , 2001, European journal of nutrition.
[107] A. Terano,et al. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. , 2001, Alimentary pharmacology & therapeutics.
[108] L. Rovati,et al. Efficacy and Safety of Oral Betaine Glucuronate in Non-alcoholic Steatohepatitis , 2000, Arzneimittelforschung.
[109] D. Russell,et al. Oxysterol biosynthetic enzymes. , 2000, Biochimica et biophysica acta.
[110] K. Itoh,et al. Regulatory mechanisms of cellular response to oxidative stress. , 1999, Free radical research.
[111] G. FitzGerald,et al. HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Vitamin E Reduces Monocyte Tissue Factor Expression in Cirrhotic Patients , 1999 .
[112] D. Russell,et al. cDNA Cloning of Mouse and Human Cholesterol 25-Hydroxylases, Polytopic Membrane Proteins That Synthesize a Potent Oxysterol Regulator of Lipid Metabolism* , 1998, The Journal of Biological Chemistry.
[113] H. Kühn,et al. The Rabbit 15-Lipoxygenase Preferentially Oxygenates LDL Cholesterol Esters, and This Reaction Does Not Require Vitamin E* , 1998, The Journal of Biological Chemistry.
[114] G. FitzGerald,et al. Enhanced lipid peroxidation in hepatic cirrhosis. , 1998, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.
[115] C. Winterbourn,et al. Hypochlorous acid-mediated modification of cholesterol and phospholipid: analysis of reaction products by gas chromatography-mass spectrometry. , 1993, Journal of lipid research.
[116] H. Shimasaki,et al. Free radical-induced liver injury. II. Effects of intraperitoneally administered 2,2'-azobis(2-amidinopropane) dihydrochloride on the fatty acid profiles of hepatic triacylglycerol and phospholipids. , 1991, Free radical research communications.
[117] H. Shimasaki,et al. Free radical-induced liver injury. I. Effects of dietary vitamin E deficiency on triacylglycerol level and its fatty acid profile in rat liver. , 1991, Free radical research communications.
[118] E. Niki. Free radical initiators as source of water- or lipid-soluble peroxyl radicals. , 1990, Methods in enzymology.
[119] C. Lieber,et al. Lipid peroxidation and antioxidant defense systems in rat liver after chronic ethanol feeding , 1989, Hepatology.
[120] M. Takahashi,et al. Oxidation of lipids. XV. Role of hydrophilic diarylamines as antioxidants in the oxidations of lipids and biological tissues. , 1988, Chemico-Biological Interactions.
[121] T. Slater,et al. Effects of α-Tocopherol on Carbon Tetrachloride Metabolism in Rat Liver Microsomes , 1987 .
[122] J. Falck,et al. Absolute configuration of the hydroxyeicosatetraenoic acids (HETEs) formed during catalytic oxygenation of arachidonic acid by microsomal cytochrome P-450. , 1986, Biochemical and biophysical research communications.
[123] E. Niki,et al. Damage to biological tissues induced by radical initiator 2,2'-azobis(2-amidinopropane) dihydrochloride and its inhibition by chain-breaking antioxidants. , 1986, Journal of free radicals in biology & medicine.
[124] G. Poli,et al. Lipid peroxidation and molecular damage to polyunsaturated fatty acids in rat liver. Recognition of two classes of hydroperoxides formed under conditions in vivo. , 1986, Chemico-biological interactions.
[125] T. Yoshikawa,et al. Effects of vitamin E on D-galactosamine-induced or carbon tetrachloride-induced hepatotoxicity. , 1982, Digestion.
[126] E. R. Davis,et al. Spin-trapping of the trichloromethyl radical produced during enzymic NADPH oxidation in the presence of carbon tetrachloride or bromotrichloromethane. , 1978, Biochimica et biophysica acta.
[127] I. Sipes,et al. Bioactivation of carbon tetrachloride, chloroform and bromotrichloromethane: role of cytochrome P-450. , 1977, Life sciences.
[128] T. Slater. Free-Radical Mechanisms in Tissue Injury , 1975 .
[129] R. O. Recknagel. Carbon tetrachloride hepatotoxicity. , 1967, Pharmacological reviews.
[130] T. Slater. Necrogenic Action of Carbon Tetrachloride in the Rat: A Speculative Mechanism Based on Activation , 1966, Nature.
[131] T. Slater,et al. Changes in liver nucleotide concentrations in experimental liver injury. 1. Carbon tetrachloride poisoning. , 1964, The Biochemical journal.
[132] N. C. Davis. The Influence of Diet upon the Liver Injury produced by Carbon Tetrachloride. , 1924, The Journal of medical research.